DexCom raises 2026 revenue guidance midpoint
DexCom posted Q2 financial results that beat expectations, driven by strong sales of its continuous glucose monitors.
The company now expects 2026 revenue of $5.18B-$5.25B, up from its previous forecast.
DexCom’s stock rose ~7% in after-hours trading following the announcement.